



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

9/2/00  
FILED  
RECEIVED  
SEP 20 2001  
TECH CENTER 1600/2900

In re application of: ALDERSON et al.

Application Serial No.: 09/499,468

Group Art Unit: 1633

Filed: February 7, 2000

Examiner: Sorbello, E.

For: Vascular Endothelial Growth  
Factor-2

Atty. Docket No.: PF112U1

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Commissioner for Patents  
Washington, D.C. 20231

Attn: Office of Initial Patent  
Examination's Customer Service Center

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:


Under the subheading "Continuing Data as Claimed by Applicant," please change the word "WHICH" to -- AND -- (each occurrence).

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red ink. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

No fee is believed required for this submission. However, should the U.S. Patent and Trademark Office determine otherwise, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3425(s). A duplicate copy of this paper is enclosed.

Respectfully submitted,

Dated: May 30, 2001

  
Michele M. Wales (Reg. No. 43,975)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, Maryland 20850  
Telephone: (301) 610-5772

Enclosures  
MMW/lcc



## UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

Bib Data Sheet

CONFIRMATION NO. 1320

SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
09/499,468	02/07/2000 RULE	435	4633 1647	PF112U1

## APPLICANTS

Ralph Alderson, Gaithersburg, MD;  
Robert Melder, Gaithersburg, MD;  
Viktor Roschke, Rockville, MD;  
Steven M Ruben, Olney, MD;  
Craig A Rosen, Laytonsville, MD;

## \*\* CONTINUING DATA \*\*\*\*\*

THIS APPLN CLAIMS BENEFIT OF 60/119,179 02/08/1999  
AND CLAIMS BENEFIT OF 60/119,926 02/12/1999  
AND CLAIMS BENEFIT OF 60/137,796 06/03/1999  
AND CLAIMS BENEFIT OF 60/171,505 12/22/1999

BL 9/12/02

## \*\* FOREIGN APPLICATIONS \*\*\*\*\*

BL 9/12/02 NONE

IF REQUIRED, FOREIGN FILING LICENSE  
GRANTED \*\* 04/24/2000

Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no	STATE OR COUNTRY MD	SHEETS DRAWING 32	TOTAL CLAIMS 41	INDEPENDENT CLAIMS 5
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature <i>[Signature]</i>	Initials <i>[Initials]</i>		

## ADDRESS

22195

## TITLE

Vascular endothelial growth factor-2

FILING FEE RECEIVED 1354	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees ( Filing )
		<input type="checkbox"/> 1.17 Fees ( Processing Ext. of time )
		<input type="checkbox"/> 1.18 Fees ( Issue )
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit

## FILING RECEIPT



\*OC000000005289675\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/499,468	02/07/2000	1632	1354	PF112U1	32	41	5

Michele M Wales Esq  
Human Genome Sciences Inc  
9410 key West Avenue  
Rockville, MD 20850

RECEIVED

AUG 3 2000

Date Mailed: 08/02/2000

HGS PATENT DEPT.

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Ralph Alderson, Gaithersburg, MD ;  
Robert Melder, Gaithersburg, MD ;  
Viktor Roschke, Rockville, MD ;  
Steven M Ruben, Olney, MD ;  
Craig A Rosen, Laytonsville, MD ;

## Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/119,179 02/08/1999  
AND WHICH CLAIMS BENEFIT OF 60/119,926 02/12/1999 \*  
AND WHICH CLAIMS BENEFIT OF 60/137,796 06/03/1999 \*  
AND WHICH CLAIMS BENEFIT OF 60/171,505 12/22/1999 \*  
(\* ) Data inconsistent with PTO records.

## Foreign Applications

If Required, Foreign Filing License Granted 04/24/2000

## Title

Vascular endothelial growth factor-2

## Preliminary Class

435

\*\*\*\*\*

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231